1-3 of 3
Michael S. Wertheim, MD
Close
Sort by
Journal Articles

Results from a Phase 1/2 Study of INCB050465, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies (CITADEL-101)

Andres Forero-Torres, MD, Rod Ramchandren, MD, Abdulraheem Yacoub, MD, Michael S. Wertheim, MD, William J. Edenfield, MD, Paolo Caimi, MD, Martin Gutierrez, MD, Luke Akard, MD, Carolina Escobar, MD, Justin Call, MD, Daniel Persky, MD, Swami P. Iyer, MD, Douglas J. DeMarini, PhD, Li Zhou, PhD, Swamy Yeleswaram, PhD, Tycel J. Phillips, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 410.
https://doi.org/10.1182/blood.V130.Suppl_1.410.410
Published: 2017
Journal Articles

An Ongoing Open-Label Phase 1/2 Study of INCB050465, a Selective PI3Kδ Inhibitor, in Patients with Previously Treated B-Cell Malignancies

Tycel Phillips, MD, Rod Ramchandren, MD, Michael S Wertheim, MD, Martin E Gutierrez, MD, William J Edenfield, MD, Fitzroy Dawkins, MD, Doug J DeMarini, Li Zhou, PhD, Swamy Yeleswaram, PhD, Robert C Newton, PhD, Xuejun Chen, PhD, Andres Forero-Torres, MD
Journal: Blood
Blood (2016) 128 (22): 4195.
https://doi.org/10.1182/blood.V128.22.4195.4195
Published: 2016
Journal Articles

Safety and Immunogenicity of Heat-Treated Zoster Vaccine (ZV HT ) In Adults with Hematologic Malignancy (HM).

Luis H. Camacho, MD, MPH, Robert F. Betts, MD, Michael S. Wertheim, MD, Yanli Zhao, PhD, Doreen A. Fernsler, BS, Susan Manoff, MD, MPH, Paula W. Annunziato, MD
Journal: Blood
Blood (2010) 116 (21): 1394.
https://doi.org/10.1182/blood.V116.21.1394.1394
Published: 2010